Tesamorelin, CJC-1295 & Ipamorelin | Triple-Action Research Blend
The Tesamorelin / CJC-1295 / Ipamorelin Blend is a sophisticated research complex that utilizes three distinct synthetic analogs to investigate the pulsatile release of growth hormone. Unlike single-peptide studies, this blend allows researchers to observe the synergistic activation of the anterior pituitary via two separate signaling pathways.
Mechanism of Action:
- Tesamorelin & CJC-1295 (The GHRH Pathway): Both act as analogs to Growth Hormone-Releasing Hormone. Tesamorelin is specifically noted for its N-terminus modification for enhanced stability, while Mod GRF 1-29 is optimized for a short but potent half-life. Together, they trigger the cAMP-PKA signaling cascade to stimulate hGH synthesis.
- Ipamorelin (The GHS Pathway): As a selective Growth Hormone Secretagogue (GHS), Ipamorelin mimics ghrelin. It activates the PLC/IP3 pathway to trigger calcium ion release, facilitating the exocytosis of growth hormone vesicles without significantly increasing stress hormones like cortisol or ACTH.
Research Potential & Observations:
- Amplified Hormone Output: Research suggests Tesamorelin can increase total GH levels (AUC) by up to 69%, while CJC-1295 analogs have shown the potential to elevate levels by 70–107% over a 12-hour window.
- IGF-1 Mediation: Studies indicate a significant rise in IGF-1—the primary mediator of anabolic growth—with some models showing up to a 122% increase during Tesamorelin testing.
- Metabolic & Structural Impact: This blend is frequently used in models studying lean muscle mass preservation, skin cell proliferation, and the reduction of visceral adipose tissue.
- Stability & Bioavailability: The specific modifications in this blend (such as the D-Alanine substitution in Mod GRF) are designed to resist enzymatic degradation, ensuring a more sustained research window.
Reviews
There are no reviews yet.